Takeda Pharmaceutical Co. Ltd. has bid €520m ($630m) to acquire Belgian biotech TiGenix NV , a company that is about to gain European approval of a cell-based treatment for complex perianal fistula in patients with Crohn's disease.
The acquisition fits with Takeda's previously stated plans to expand its portfolio of products in late-stage development in priority fields. TiGenix's Alofisel (darvadstrocel; Cx601) will add to Takeda's gastroenterology pipeline...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?